Lincoln Pharmaceuticals Limited

NSE:LINCOLN.NS

659.3 (INR) • At close November 4, 2024
Overview | Financials

Numbers are in millions (except for per share data and ratios) INR.

20232022202120202019201820172016201520142013201220112010200920082007
Revenue 5,805.4965,103.0884,681.9744,147.4793,768.4063,569.1953,549.9973,606.4264,001.5042,660.7452,112.6691,928.7871,754.5661,826.8661,267.2841,144.412862.319
Cost of Revenue 3,918.632,413.9692,197.8721,988.8221,837.4711,764.7921,935.9782,371.7692,959.2571,909.8161,463.2871,323.6141,172.2391,277.466783.6911,047.83768.634
Gross Profit 1,886.8662,689.1192,484.1022,158.6571,930.9351,804.4031,614.0181,234.6571,042.247750.928649.383605.174582.326549.4483.59296.58293.685
Gross Profit Ratio 0.3250.5270.5310.520.5120.5060.4550.3420.260.2820.3070.3140.3320.3010.3820.0840.109
Reseach & Development Expenses 109.712117.691093.63282.99689.38370.91652.97955.8845.99530.96430.01800000
General & Administrative Expenses 1,031.41933.297178.192138.246113.673107.17675.86726.834130.75595.63961.0765.79480.56380.71373.68300
Selling & Marketing Expenses 42.77648.085251.542229.117244.128177.372187.632248.817217.874220.524190.325210.426205.753224.649187.00800
SG&A 994.016981.382429.734367.363357.801284.548263.499275.651348.629316.163251.395276.22286.315305.362260.69100
Other Expenses 344.225224.72999.97756.6390.0110.163.001536.983330.821209.43218.132181.619175.663129.885115.0255.9566.813
Operating Expenses 994.0161,888.7491,600.1671,361.9451,323.1261,190.061,139.75812.634679.451525.593469.527457.838461.978435.247375.7165.9566.813
Operating Income 892.85805.469876.979798.009583.389608.204474.268422.023362.796225.335179.855147.335120.348114.153107.87790.62686.872
Operating Income Ratio 0.1540.1580.1870.1920.1550.170.1340.1170.0910.0850.0850.0760.0690.0620.0850.0790.101
Total Other Income Expenses Net 329.576199.32982.41439.19988.93713.742-11.798-53.592-32.141-26.878-59.142-33.496-46.465-31.798-22.04-19.944-21.67
Income Before Tax 1,222.4261,004.798959.394837.205672.324621.945462.471368.43330.655198.457120.713113.8473.88382.35585.83770.68265.202
Income Before Tax Ratio 0.2110.1970.2050.2020.1780.1740.130.1020.0830.0750.0570.0590.0420.0450.0680.0620.076
Income Tax Expense 289.377275.805265.843214.708157.661134.557115.97797.5492.65848.04318.86718.49722.60323.85724.793018.576
Net Income 933.049728.993693.55622.501514.394487.101346.23270.648236.823150.121106.54396.62351.18841.66461.04370.68246.626
Net Income Ratio 0.1610.1430.1480.150.1370.1360.0980.0750.0590.0560.050.050.0290.0230.0480.0620.054
EPS 46.5836.434.6331.0825.7224.3617.3115.7314.529.26.535.923.143.026.715.726.13
EPS Diluted 46.5836.434.6331.0825.7224.3617.3115.7314.169.26.535.923.143.026.715.726.13
EBITDA 999.0971,116.761,020.899895.631768.314717.818570.32491.787453.363317.709215.346155.996122.408130.821119.48299.25393.939
EBITDA Ratio 0.1720.2190.2180.2160.2040.2010.1610.1360.1130.1190.1020.0810.070.0720.0940.0870.109